T he migration of T cells from the blood into sites of acute and chronic inflammation is controlled, in part, by specific molecular interactions between T cells and endothelial cells lining vessels within the affected tissue (1) . The vascular adhesion receptors P-and E-selectin are induced early during inflammatory/immune responses in tissues and mediate the initial recruitment of several types of leukocytes including T cells (1) (2) (3) . Binding sites for the selectins are constitutively expressed by granulocytes and transcriptionally induced during Ag-driven lymphocyte proliferation (2, 3) .
P-selectin glycoprotein ligand 1 (PSGL-1) 3 is a ligand for both P-selectin and E-selectin (2, 4 -7) . PSGL-1 purified from cultured human (8) and murine (9) T cells reacts with the HECA-452 Ab in Western blots. The HECA-452 Ab recognizes carbohydrate structures with E-selectin-binding activity and partially blocks E-selectin-mediated T cell adhesion in vitro (10, 11) . In mice, PSGL-1-deficient T cells develop relatively low levels of E-selectin-binding activity during short-term culture in vitro and show reduced levels of E-selectin-mediated trafficking in vivo (12) . On the other hand, PSGL-1 is not required for the development of E-selectin-binding activity on many human leukocytic cell lines (13) . The PSGL-1-specific mAb KPL-1 completely blocks the interaction of human leukocytes with P-selectin, but does not affect their rolling on Eselectin (13) . In addition, circulating leukocytes in PSGL-1-deficient animals are devoid of P-selectin-binding activity but still interact with E-selectin in vitro and in vivo (14) . Finally, the porcine E-selectin/Ig chimera P11.4 precipitates several glycoproteins from detergent lysates of HECA-452-positive human T cells other than PSGL-1, suggesting that multiple binding sites may support rolling activity in vivo (15) .
Several lines of evidence suggest that L-selectin (CD62L) serves as a ligand for E-selectin on neutrophils. CD62L on human neutrophils is recognized by the HECA-452 mAb (16) and recombinant E-selectin/Ig chimeras precipitate neutrophil CD62L from detergent lysates (15, 17) . Anti-CD62L mAbs partially block neutrophil adhesion to E-selectin (15) (16) (17) (18) , though blockade of leukocyte-on-leukocyte rolling may partially account for this effect (18, 19) . In contrast, HECA-452 does not recognize CD62L on most circulating human lymphocytes (16) and E-selectin/Ig chimeras do not precipitate appreciable amounts of CD62L from detergent lysates of resting human, bovine, or mouse lymphocytes (9, 15) . Thus, CD62L carries E-selectin binding sites on neutrophils, but not, it appears, on most circulating lymphocytes.
Structural analysis of E-selectin ligands on circulating human T cells is difficult because only a small fraction of the cells in most individuals express functional binding sites (20) . In addition, effector T cells are rapidly cleared from the circulation thus comprise a small percentage of the circulating pool in healthy individuals. Consequently, the existing studies of circulating PBL may not detect ligands expressed transiently by recently activated T lymphoblasts. Previous studies showed that phorbol ester treatment of the Jurkat T cell line and anti-CD3/IL-2-driven culture of normal human T cells induced synthesis of E-selectin ligands (21, 22) . Therefore, the current study investigated the structure and function of E-selectin binding sites induced by phorbol ester treatment of the Jurkat T cell line and anti-CD3/IL-2-driven proliferation of human PBL. In both cases, T cell activation induced synthesis of E-selectin binding sites on CD62L that supported rolling activity under flow conditions.
Materials and Methods

Human PBL, cell lines, and in vitro culture conditions
Human blood from healthy adult donors was collected into citrate anticoagulant and the mononuclear cell fraction was isolated following centrifugation through Histopaque 1077 (Sigma-Aldrich, St. Louis, MO). The cells were washed in HBSS and prepared for flow cytometric analysis, biotin-labeling procedures, or in vitro culture. For the latter, 1 ϫ 10 7 cells were resuspended at 2 ϫ 10 6 cells/ml in plates with immobilized anti-CD3 for 24 h, collected, and then cultured in XVIVO 15 medium containing 1.5 ng/ml IL-2, as described previously (21, 22) . Cells were collected at various intervals after initiation of the cultures for analysis. After 6 days, some cultures were restimulated by another round of CD3 cross-linking and cultured with IL-2 for an additional 3 days. The human Jurkat T cell line was cultured and stimulated with phorbol ester as previously described (21) . In some experiments, T cells were treated with neuraminidase (0.1 U/ml in low pH buffer (from Vibrio cholerae; Calbiochem, La Jolla, CA)) for 30 min before the flow cytometric or immunoprecipitation analyses described below. Control cells were treated with the low pH buffer alone.
Reagents and flow cytometric analysis
The following mAbs were used: DREG 56 and DREG 200 (mouse antihuman CD62L mAbs (23)), PL2 (mouse anti-PSGL-1; Serotec, Oxford, U.K.), and HECA-452 (rat IgM anti-human cutaneous lymphocyte-associated Ag (11)). The P11.4 pig E-selectin/human Ig chimera was used as described in our earlier analysis of human T cells (15) . Flow cytometric analysis was done as previously described (15) . Briefly, 1 ϫ 10 6 cells were labeled with DREG 56 or HECA-452 followed by appropriate rat or mouse Ig-specific second-stage reagents (Jackson ImmunoResearch Laboratories, West Grove, PA). Negative controls included second-stage reagent alone or in combination with an irrelevant isotype-matched negative control. In some experiments, cells were stained with the P11.4 E-selectin chimera followed by PE-labeled anti-human Ig second stage (Jackson ImmunoResearch Laboratories). The specificity of the chimera binding was confirmed by blocking with EDTA, as previously described (15) . For two-color stains, Jurkat T cells were labeled with P11.4 and HECA-452 in the first step and PE-anti-human Ig and FITC-anti-rat Ig second stages were then added. Appropriate controls were done to ensure that the reactivity of the secondstage Abs was specific. The effect of DREG 56 on the binding of P11.4 to Jurkat T cells was determined by first pretreating the cells with 50 g/ml DREG 56 for 30 min on ice. The cells were then stained with P11.4 followed by the anti-human Ig second-stage reagent. All analyses were done on a BD FACSCalibur (BD Biosciences, Mountain View, CA).
Surface biotin labeling
For biotin labeling of surface Ags, 1 ϫ 10 8 PMA-treated Jurkat cells or cultured human T cells were washed three times with sterile PBS and resuspended in 1 ml of sulfo-N-hydroxysuccinimide-LC-biotin/PBS (550 g/ml; Pierce, Rockford, IL). After a 30-min incubation at room temperature, cells were washed three times with PBS and lysed for 2-3 h on ice with Nonidet P-40 lysis buffer (2% Nonidet P-40, 100 mM NaCl, 1 mM MgCl 2 , 1 mM CaCl 2 , 5 mM NaN 3 , 10 mM HEPES, and the following protease inhibitors: pepstatin A, 1,10-phenanthroline, PMSF, benzamidine, antipain, leupeptin, and chymostatin (Sigma-Aldrich)). To remove all nonspecific reactive components in the lysates, rabbit serum (5%) was added, the lysates were incubated for 1 h at room temperature, and then extensively precleared with protein G (Boehringer Mannheim, Indianapolis, IN) overnight at 4°C with constant rotation. The protein G beads were subsequently removed and the lysates were either used immediately or frozen at Ϫ80°C. Precleared biotin lysates were then incubated with 40 -50 g/ml E-selectin chimera or 100 g/ml mAb for 1 h at room temperature. The chimera-ligand complexes were then precipitated with protein G at 4°C overnight under constant rotation. The beads were washed three times with wash buffer and mixed with nonreducing loading buffer and loaded onto 8% SDS-polyacrylamide gels. Gels were electrophoresed under nonreducing conditions and transferred to polyvinylidene difluoride membranes (Bio-Rad, Hercules, CA). After transfer, membranes were washed briefly with 1ϫ TBST (10 mM Tris (pH 8.0), 150 mM NaCl, and 0.05% Tween 20) and then blocked with 7% BSA/TBST for 2 h at room temperature. Membranes were then washed with several changes of 1ϫ TBST for 1.75 h. Streptavidin-HRP conjugate (Amersham Life Science, Buckinghamshire, U.K.) was diluted 1/5000 in sterile PBS and incubated with the membrane for 40 min and then washed for 1.75 h with several changes of 1ϫ TBST. ECL detection reagents were used according to the manufacturer's recommendations (Amersham Life Science) and incubated with the membranes for 1 min. Membranes were then covered with cellophane and exposed to X-OMAT film (Kodak, Rochester, New York) for 1-10 min, and the film was developed.
Precipitation and Western blot analysis
Detergent lysates prepared from unlabeled cells were precleared with rabbit serum and protein G, precipitated with the P11.4 chimera, and then run on an 8% nonreducing SDS-PAGE gel. For the Western blot procedures, the resolved glycoproteins were transferred to nitrocellulose and probed with DREG 56, DREG 200, or negative controls using a miniblotter apparatus (Immunetics, Cambridge, MA). The blots were developed as previously described (15) .
In vitro rolling assay
In vitro rolling assays were done as previously described (24) . Briefly, for most experiments, human E-selectin cDNA-transfected mouse L cells were grown to confluency on the internal surface of small 1-cm long capillary tubes (1.5-mm diameter). For others, recombinant human E-and P-selectin/IgG chimeras (prepared from constructs provided by B. Seed, Massachusetts General Hospital, Boston, MA), used as described in a previous report (22) , were immobilized on the internal surface of the capillary tubes. For the latter, anti-human Ig (Sigma-Aldrich) was used to capture the Eand P-selectin/IgG chimeras from culture supernatant fluids. The capillary tubes were integrated into a closed loop system (ϳ120 cm) in which 3 ml of fluid (DMEM plus 5% FBS) was recirculated via a peristaltic pump, and mounted on the stage of an inverted microscope (Nikon, Melville, NY) set up for video microscopy (Sony charge-coupled device camera; Sony, Tokyo, Japan).
Lymphocytes (2 ϫ 10 6 /ml) were injected into the closed system and their interaction with the E-selectin transfectants or selectin/Ig chimeras analyzed under a flow rate that produced shear of 2 dynes/cm 2 . Interactions were monitored at the beginning of the capillary tube. Once a rolling interaction was established, isotype-matched negative control (GD3.8) and the anti-CD62L mAbs were injected sequentially at 50 g/ml concentrations. The number of cells rolling on the immobilized E-selectin was measured at 1-min intervals for 3 min following injection of each Ab. Since the maximal number of rolling cells varied with each cell population (maximum ranged from ϳ20 to 200), the data are reported as the percentage of the maximum number of rolling cells in a given assay. At the cell concentration used, rolling cells were in contact with the immobilized E-selectin substrate but not with each other. Therefore, the loss of cells from the capillary surface reflected, primarily, inhibition of lymphocyte-E-selectinadhesive interactions as reported previously (24) .
Results
Anti-CD62L mAb blocks E-selectin/Ig chimera binding to phorbol ester-stimulated Jurkat cells
The Jurkat T cell line was stimulated with 5 nM PMA for 3 days and its capacity to bind P11.4 examined by flow cytometry. As shown in Fig. 1 (Fig. 2) . In contrast, isotype-matched negative control mAb had no effect in this assay.
E-selectin/Ig chimera precipitates CD62L from detergent lysates of activated Jurkat T cells
The P11.4 chimera precipitated two major biotinylated molecules from the detergent lysate of phorbol-treated, surface-biotinylated Jurkat cells. These species migrated as 70-to 80-and 120-to 130-kDa glycoproteins under nonreducing conditions on SDS-PAGE (Fig. 3) . A minor band migrating at 180 -220 kDa was detected in some precipitates as well (Fig. 3A, lane 1) . DREG 56 also precipitated a biotinylated species migrating at 70 -80 kDa from the detergent lysate (Fig. 3A, lane 2) . Preclearing experiments using DREG 56 confirmed the identity of the 70-to 80-kDa glycoprotein precipitated by P11.4 as CD62L (Fig. 3B) . A human P-selectin/Ig chimera showed no reactivity for CD62L (data not shown), indicating that this interaction was specific to E-selectin. Thus, CD62L is one of two major glycoproteins that react with the P11.4 chimera in extracts of surface-biotinylated, phorbol estertreated Jurkat cells.
E-selectin/Ig chimera precipitates CD62L from cultured human PBL
Our previous study found that P11.4 precipitated three major structures from the surface of biotinylated human PBL that migrated at 120 -130, 220 -230, and 260 kDa (15) . In the current study, PBL were activated on plate-immobilized anti-CD3 and cultured in IL-2 (two cycles) to up-regulate selectin ligand synthesis before biochemical analysis (21, 22) . P11.4 precipitated four major structures from cultured human PBL that migrated at 70 -80, 120 -130, 220 -230, and 260 kDa under nonreducing conditions (Fig. 4A, lane 2) . The DREG 56 mAb precipitated material that comigrated with the 70-to 80-kDa band in the P11.4 precipitate (Fig. 4A, lane 1) . In addition, DREG 56 reacted with the 70-to 80-kDa band in Western blots prepared from the P11.4 precipitate (Fig. 4B, lanes 2 and  3) . Neuraminidase treatment reduced L-selectin size by 5-10 kDa and eliminated all reactivity with the P11.4 chimera in the precipitation assay (data not shown). Finally, the anti-PSGL-1-specific mAb PL-2 (Fig. 4C) and a P-selectin/Ig chimera (data not shown) both precipitated a single band that comigrated with the 220-to 230-kDa band in the P11.4 precipitate. Thus, P11.4 reacts with CD62L, PSGL-1, and two as yet unidentified structures on cultured human PBL.
The expression of P11.4-reactive CD62L was compared in fresh and cultured PBL. PBL containing ϳ10 -20% HECA-452-positive T cells were cultured for either one (3 days) or two cycles (9 days) using immobilized anti-CD3 and IL-2. DREG 56 and the P11.4 precipitations were performed on detergent extracts prepared from equal numbers of biotinylated fresh and cultured cells. Extracts of both the fresh (0 days) and one-cycle (3 day) blasts contained relatively small amounts of the 70-to 80-kDa P11.4-reactive material, despite large overall recoveries of CD62L with the DREG 56 mAb (Fig. 5A) . In contrast, P11.4 and DREG 56 precipitated nearly similar quantities of CD62L from the two-cycle (9 days) T cell blasts. If DREG 56 precipitated nearly all soluble CD62L in the extracts, then ϳ60 -70% of the available CD62L from twocycle blasts was also precipitated by P11.4 (Fig. 5B) . This compared with ϳ20% in either the fresh or one-cycle blasts.
Anti-CD62L partially blocks the rolling of cultured T lymphoblasts on human E-selectin, but not P-selectin
The relationship between time in culture and the development of CD62L-mediated rolling on human E-selectin cDNA transfected L cells was investigated. The greatest number of rolling cells was seen in the 9-day culture, whereas time zero had the fewest (data not shown). Anti-CD62L had no effect on the rolling of fresh (day 0) and one cycle (day 3) cells. In contrast, anti-CD62L dissociate ϳ40% of the T lymphoblasts cultured for 9 days (Fig. 6) . The rolling speeds of lymphocytes before and after the injection of anti-CD62L mAbs were highly variable and showed no statistically significant differences (data not shown). Subsequent injection of an anti-E-selectin mAb blocked the interaction completely (data not shown). The 9-day cultured T lymphoblasts rolled on human Pand E-selectin chimeras as well (Fig. 7) . The DREG 56 mAb reversed ϳ40% of the rolling on E-selectin but did not inhibit interactions with P-selectin. Therefore, CD62L on 9-day cultured T lymphoblasts contributes to rolling on E-selectin, but not P-selectin under flow conditions.
Discussion
This study shows that under appropriate conditions, CD62L on human T cells is modified to interact with E-selectin. Both phorbol ester stimulation of Jurkat T cells and anti-CD3/IL-2-driven culture of PBL induced E-selectin binding sites on CD62L. In stimulated/cultured T cells, the DREG 56 mAb partially blocked staining with the porcine E-selectin/Ig chimera (P11.4) and rolling on immobilized E-selectin under flow. Furthermore, the P11.4 chimera precipitated CD62L from extracts of both phorbol estertreated Jurkat cells and cultured PBL providing direct evidence for ligand activity. PSGL-1 was also identified in the P11.4 precipitates, confirming previous observations that T cell PSGL-1 is a ligand for E-selectin on both fresh and cultured PBL (8, 9, 12) .
The P11.4 chimera did not appreciably interact with CD62L on freshly isolated human PBL; however, the prevalence of the Eselectin binding variant of CD62L increased with time in culture following anti-CD3/IL-2 stimulation. Approximately 40% of the cultured T lymphoblasts that rolled on immobilized human E-selectin dissociated from the substrate and the formation of new attachments was blocked by anti-CD62L mAb. Importantly, the anti-CD62L mAb did not inhibit rolling on P-selectin. This finding rules out anti-CD62L-mediated inhibition of leukocyte-leukocyteadhesive interactions as a contributing factor in our flow system. In such interactions, the carbohydrate-binding domain of CD62L interacts with PSGL-1 on adherent leukocytes (25) . If the impact of anti-CD62L on E-selectin rolling reflected inhibition of leukocyteleukocyte interactions then one would expect the mAb to inhibit T lymphoblast rolling on immobilized P-selectin equally well. It does not; therefore, we conclude that the E-selectin-binding variant of CD62L identified in extracts of cultured T lymphoblasts supports rolling activity on immobilized E-selectin. This ligand is not, it appears, a major E-selectin binding site on circulating HECA-452-positive memory cells, but develops during T lymphoblast differentiation in vitro.
The activation conditions used in the current study share several important features. Phorbol ester stimulation of Jurkat T cells and anti-CD3/IL-2-driven T cell proliferation in the serum-free medium XVIVO-15 induce synthesis of the fucosyltransferase VII enzyme (FucTVII) (21, 22) . This enzyme is required for construction of all selectin ligands (26) and its activity determines, in part, the density of E-and P-selectin ligands on T cells (22) . Consequently, the current findings imply that under appropriate in vitro conditions human CD62L is one of several substrates for the FucT-VII enzyme in human T cells.
Previous studies showed that phorbol ester treatment of both Jurkat T cells and human T cell cultures induces CD62L shedding initially, followed by increased CD62L synthesis and restoration of surface levels (27) . Therefore, the E-selectin-binding variant of CD62L accumulates under activation conditions that promote the synthesis of both CD62L and FucTVII. Such conditions may occur during T cell differentiation in human lymph nodes and persist on the effector T cells that accumulate in E-selectin-mediated cutaneous immunologic lesions. Specifically, high levels of CD62L and the FucTVII-dependent epitope HECA-452 are expressed on a subset of actively differentiating T cells recovered from peripheral lymph nodes and on most T cells recruited into skin blisters (28, 29) . Thus, effector cells that are rapidly cleared from the circulation into tissues may transiently synthesize the E-selectin-binding variant of CD62L. This hypothesis as well as how the in vitro activation parameters used in this study resemble those in vivo are currently under investigation. Nonetheless, the current findings indicate that CD62L is one of very few glycoproteins on human T cells that develop E-selectin-binding activity during T cell proliferation/differentiation in vitro and support rolling on E-selectin at physiologically meaningful levels of shear stress.
The biotinylation procedure used in the current study ensures that the receptors precipitated by the P11.4 chimera are expressed on the cell surface. Therefore, CD62L and PSGL-1 derived from the cell surface of cultured PBL are readily precipitated by the E-selectin chimera yet mAbs directed at these receptors do not completely inhibit tethering/rolling on immobilized E-selectin under flow conditions. As previously reported, the PSGL-1 mAb FIGURE 7. Anti-CD62L mAb partially blocks activated T cell rolling on immobilized E-selectin chimera. PBL were cultured as described in Fig.  5 legend. Rolling assays were performed on immobilized IgG/E-selectin (human) and IgG/P-selectin (human) chimeras. The control mAb (time 0) was administered first, followed by the DREG 56 mAb. The bars show T lymphoblasts rolling on the immobilized selectin chimeras at 1, 2, and 3 min after DREG 56 infusion. The values reflect the mean Ϯ SEM of three experiments for the E-selectin assays, and mean Ϯ range of two experiments for the P-selectin assays. The reduction in E-selectin-dependent rolling at 3 min was significant at a value of p Ͻ 0.05.
FIGURE 5.
Precipitation of CD62L by P11.4 at different time points following CD3 cross-linking and in vitro culture. PBL were cultured as described in Materials and Methods. At time 0, day 3, and day 9 (3 days after second round of CD3 cross-linking), the same number of lymphocytes were labeled with biotin, lysed, and processed as described in Fig. 4 legend. A, SDS-PAGE gel comparing the P11.4 E-selectin chimera and the DREG 56 anti-CD62L mAb precipitates at the three time points. B, Densitometric analysis of the regions contained in the boxed area in A. The smaller bands below the box were not always seen and were excluded from the analysis. FIGURE 6. Anti-CD62L mAb partially blocks activated human T cell rolling on E-selectin transfectants. PBL were cultured as described in Fig.  5 legend. Rolling assays were performed in a closed loop capillary system at the indicated times on E-selectin cDNA-transfected mouse L cells as described in Materials and Methods. T lymphoblast rolling on L cells was allowed to stabilize before infusion of Abs. The isotype control (GD3.8) was injected first and its effect was monitored for 3 min. The anti-CD62L mAb DREG 56 was then injected and its effect was monitored for the same length of time. Each curve depicts an independent experiment. KPL-1 did not block T lymphoblast rolling on E-selectin (data not shown) and the anti-CD62L mAb DREG 56 showed only partial inhibition (40%). The adhesive domains of the selectins and their ligands are generally localized to specialized regions of the molecules. Consequently, not all mAbs that react with the molecules inhibit adhesive activity. Furthermore, the E-selectin-binding domains of both molecules may consist primarily of carbohydrate thus constitute poor targets for mAb production. In addition, multiple glycoconjugates may contribute to rolling activity under flow conditions so that blockade of individual ligands does not dissociate all cells. For example, the P11.4 precipitates from resting (15) and cultured PBL contain a major band migrating at 130 kDa in SDS-PAGE gels that is distinct from both CD62L and PSGL-1. The structure and physiologic relevance of this as yet unidentified E-selectin ligand is currently under study.
In summary, we show for the first time that lymphocyte CD62L is one of four surface molecules on activated T lymphoblasts that interact directly with E-selectin. Blockade of CD62L alone is sufficient to partially block the rolling of cultured PBL on immobilized E-selectin under conditions that minimize the impact of CD62L-mediated leukocyte-leukocyte rolling interactions. Thus, as previously shown for neutrophils (15) (16) (17) , CD62L is both a carbohydrate-binding receptor for ligands on target cells and a scaffold for oligosaccharides that interact directly with E-selectin.
